Baclofen
( DrugBank: Baclofen / KEGG DRUG: Baclofen )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 10 | Charcot-Marie-Tooth disease | 21 |
| 13 | Multiple sclerosis | 14 |
| 18 | Spinocerebellar degeneration | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
| 206 | Fragile X syndrome | 2 |
2. Amyotrophic lateral sclerosis
Clinical trials : 786 / Drugs : 550 - (DrugBank : 182) / Drug target genes : 170 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
10. Charcot-Marie-Tooth disease
Clinical trials : 45 / Drugs : 34 - (DrugBank : 10) / Drug target genes : 12 - Drug target pathways : 22
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
18. Spinocerebellar degeneration
Clinical trials : 83 / Drugs : 83 - (DrugBank : 31) / Drug target genes : 30 - Drug target pathways : 53
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
65. Primary immunodeficiency
Clinical trials : 798 / Drugs : 585 - (DrugBank : 118) / Drug target genes : 100 - Drug target pathways : 216
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
149. Hemiconvulsion hemiplegia epilepsy syndrome
Clinical trials : 34 / Drugs : 37 - (DrugBank : 16) / Drug target genes : 17 - Drug target pathways : 30
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
206. Fragile X syndrome
Clinical trials : 118 / Drugs : 75 - (DrugBank : 30) / Drug target genes : 58 - Drug target pathways : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
